Topics

MorphoSys, Galapagos Halt Development of Atopic Dermatitis Candidate Licensed to Novartis

11:30 EDT 29 Oct 2019 | Genetic Engineering News

MorphoSys and Galapagos are halting development of MOR106—an atopic dermatitis candidate the companies licensed to Novartis last year for potentially more than $1 billion—after an interim futility analysis of a Phase II trial showed the drug was unlikely to meet the study’s primary endpoint

The post MorphoSys, Galapagos Halt Development of Atopic Dermatitis Candidate Licensed to Novartis appeared first on GEN - Genetic Engineering and Biotechnology News.

Original Article: MorphoSys, Galapagos Halt Development of Atopic Dermatitis Candidate Licensed to Novartis

NEXT ARTICLE

More From BioPortfolio on "MorphoSys, Galapagos Halt Development of Atopic Dermatitis Candidate Licensed to Novartis"

Quick Search

Relevant Topics

Eczema
Eczema is a common itchy skin disease characterized by reddening and vesicle formation, which may lead to weeping and crusting. It is endogenous, or constitutional. There are five main types; atopic, seborrhoeic, discoid, gravitational or varicose. ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...